Overview
MAIA market data
Price History
MAIA price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for MAIA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung CancerBenzinga · Jul 8, 2026, 2:01 PM
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung CancerBenzinga · Jun 25, 2026, 12:15 PM
MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung CancerBenzinga · Jun 18, 2026, 12:45 PM
MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign CountriesBenzinga · Jun 4, 2026, 1:55 PM
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201KBenzinga · Jun 2, 2026, 1:54 PM
MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical OncologyBenzinga · Jun 1, 2026, 12:05 PM
8-K filing — MAIA Biotechnology, Inc. (MAIA)SEC EDGAR · May 14, 2026, 9:02 PM
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) EstimateBenzinga · May 11, 2026, 1:31 PM